Cervical-uterine cancer is among the most feared chronic degenerative diseases, due its high mortality and morbidity rates. This study describes women's feelings before a preventive examination for cervical-uterine cancer, through a case study based on observations and semi-structured interviews as data collection techniques. A total of 24 women were interviewed, between eighteen and sixty years old, who attended the cancer prevention unit at a basic healthcare clinic in Fortaleza, Ceará State between April and August 2004. This study shows that women generally request these preventive examinations only when symptoms appear. They view this procedure with apprehension and fear, due to the possibility of a positive diagnosis of cervical-uterine cancer; they feel embarrassed at exposing their bodies for examination, particularly by male physicians; and they are poorly informed about their own bodies and even their own sexuality. These findings highlight the need for healthcare practitioners to conduct educational activities for women, in order to enhance professional relationships between healthcare providers and users, helping lower the rate of this type of cancer through more frequent preventive examinations.

Download full-text PDF

Source
http://dx.doi.org/10.1590/s1413-81232007000300024DOI Listing

Publication Analysis

Top Keywords

cervical-uterine cancer
16
preventive examinations
12
cancer case
8
cancer
6
[women's perceptions
4
preventive
4
perceptions preventive
4
cervical-uterine
4
examinations cervical-uterine
4
case study]
4

Similar Publications

Background: Breast cancer and reproductive system cancers remain significant public health threats for Chinese women. This study aimed to evaluate the latest epidemiological patterns and trends of four female-specific cancers in China.

Methods: The year- and age-specific estimates of the incidence, mortality, and disability-adjusted life-years (DALYs) associated with breast, cervical, ovarian, and uterine cancers in China from 1990 to 2021 were generated from the Global Burden of Disease, Injuries, and Risk Factors 2021 study.

View Article and Find Full Text PDF

Living in a food desert in Louisiana and its effects on gynecologic cancer outcomes.

Gynecol Oncol

December 2024

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Miami, Sylvester Cancer Center, Miami, FL, United States of America. Electronic address:

Objective: Food insecurity is becoming recognized as an important measure of public health. Louisiana has a poorer health index and a higher food insecurity rate than the national average. This study aims to investigate how living in a food desert affects the stage at diagnosis and 5-year overall survival in patients with gynecologic cancers.

View Article and Find Full Text PDF

In 2019, 1.8 million new cancer cases occurred, and 500,000 cancer deaths were expected in the United States, costing $21 billion. Regular primary care screenings have correlated with early cancer detection, treatment, health promotion, and reduced costs.

View Article and Find Full Text PDF

Gynecological cancer is a term referring to malignancies that typically involve ovarian, cervical, uterine, vaginal, and vulvar cancer. Combined, these cancers represent major causes of morbidity and mortality in women with a heavy socioeconomic impact. MiRNAs are small non-coding RNAs that are intensively studied in the field of cancer and changes in them have been linked to a variety of processes involved in cancer that range from tumorigenesis to prognosis and metastatic potential.

View Article and Find Full Text PDF

Systemic hormone therapy after breast and gynecological cancers: an Italian expert group consensus opinion.

Climacteric

November 2024

Coordinator of the Italian Group of Special Interest on Menopause of the Italian Society of Obstetrics and Gynecology, Women's Wellness Foundation, Cagliari, Italy.

Article Synopsis
  • * ET/HT can be cautiously used after vulvar cancers, melanoma, and certain endometrial cancers, while more caution is needed with adenocarcinomas and uterine sarcomas.
  • * For breast cancer survivors, ET/HT is likely safe after ER/PR-negative cancers but should be applied carefully after ER/PR-positive cases.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!